Compare Eli Lilly And Co (LLY) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Oracle Corporation — how do they compare? Eli Lilly And Co trades at $1,159.69 (market cap $1.02T), while Oracle Corporation trades at $125.98 (market cap $349.63B). The key difference: Eli Lilly And Co is far larger — about 2.9× Oracle Corporation's market cap, and Oracle Corporation pays the higher dividend (1.65%). Which is the better fit depends on your goals.
| LLY | ORCL | |
|---|---|---|
Market Cap | $1.02T | $349.63B |
Sector | Health | Technology |
52-Week High | $1.24K | $328.33 |
52-Week Low | $625.65 | $121.37 |
Enterprise Value | $1.06T | $478.88B |
Dividend Yield | 0.6% | 1.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Oracle (ORCL) trades at $126.48, up 1.78% today, with a strong fundamental backdrop including revenue growth to $57.40B in 2025 and a net income margin of 25.37%. Recent quarters have consistently beaten EPS estimates, and analyst consensus is bullish with a $253.30 price target. Technicals show a bearish overall signal but with bullish oscillators, and the stock faces support near $125.
The outlook is positive given Oracle's AI infrastructure expansion and earnings momentum, but risks include high debt levels and competitive pressures. The stock offers growth potential if execution continues, yet investors should weigh valuation multiples against sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
